Business
First Prospective Clinical Validation of Allarity's DRP® Companion Diagnostic to be Presented at 2023 ASCO Annual Meeting
Phase 2 study evaluating the utility of a DRP® companion diagnostic for cisplatin supports its ability to predict drug response in certain breast cancer
About this update from Allarity Therapeutics, Inc.
[{"type":"text","content":"Phase 2 study evaluating the utility of a DRP® companion diagnostic for cisplatin supports its ability to predict drug response in certain breast cancer patients Boston, MA (May 30, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced the results of a prospective Phase 2 clinical study of the Company’s proprietary DRP® technology that will be presented in a poster at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on June 3, 2023. In the Phase 1/2 study, researchers analyzed the transcriptomic profiles of 37 evaluable metastatic breast cancer (mBC) patients and, based on analysis of biomarkers comprised within a DRP® signature, assigned response likelihood scores (DRP® 0-100) of patient tumors to a targeted, liposomal form of cisplatin (LiPlaCis™). Data from the poster presentation will show that the cisplatin-DRP® identified all four mBC patients who demonstrated a partial response (PR) in the trial as likely responders to the LiPlaCis™ treatment regimen using a DRP80+ score as a cut-off for likely responders. In addition, the cisplatin-DRP® also identified mBC patients demonstrating other efficacy signals, including improved progression-free survival. Based on these data, researchers concluded that the cisplatin-DRP® companion diagnostic can differentiate, in a statistically significant way, clinical responders and non-responders to cisplatin administered as LiPlaCis™. “While our proprietary DRP® companion diagnostics have been extensively validated in numerous retrospective analyses across multiple forms of cancer and many drug types, these data represent the first prospective clinical study showing that our technology can predict actual patient responses ahead of potential treatment,” said James G. Cullem, Chief Executive Officer of Allarity Therapeutics. “The ability to differentiate likely responders to a specific drug regimen prior to treatment has the potential to provide improved patient benefits and potential clinical trial efficiencies, and we are excited that these data will be shared with our colleagues at this year’s ASCO meeting.” Using a proprietary systems biology algorithm, Allarity’s DRP® technology...